<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02758366</url>
  </required_header>
  <id_info>
    <org_study_id>GBMTMZ/DOX2015</org_study_id>
    <secondary_id>2015-002307-28</secondary_id>
    <nct_id>NCT02758366</nct_id>
  </id_info>
  <brief_title>Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma</brief_title>
  <official_title>An Open-label, Single-arm, Phase II Study to Evaluate Safety and Efficacy of Doxorubicin in Combination With Radiotherapy, Temozolomide and Valproic Acid in Patients With Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meyer Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meyer Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard therapy of glioblastoma (GBM) consists of gross total resection followed by
      focal irradiation to the tumor bed with concomitant and adjuvant temozolomide (TMZ). The
      association of valproic acid and TMZ during radiotherapy improves survival of GBM.
      Preclinical studies suggested that doxorubicin had a strong antineoplastic activity against
      human gliomas. Moreover, some studies showed that the continuous infusion of anthracyclines
      in patients with solid tumor ensured a better safety profile compared with bolus
      administration.

      Based on these findings, the purpose of this study is to evaluate safety and efficacy of
      prolonged administration of doxorubicin in combination with radiotherapy, temozolomide and
      valproic acid in pediatric and adult patients with newly diagnosed GBM and diffuse intrinsic
      pontine glioma (DIPG).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to early discontinuation of the study drug (doxorubicin)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-related serious adverse events (SAE) as assessed by CTCAE v4.0</measure>
    <time_frame>32 months</time_frame>
    <description>Number of patients with SAE and SAE leading to withdrawal from the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients who died for SAE as assessed by CTCAE v4.0</measure>
    <time_frame>32 months</time_frame>
    <description>Mortality due to adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients who undergone to withdrawal of doxorubicin</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of early suspension of the study drug (doxorubicin)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event free survival</measure>
    <time_frame>2 months</time_frame>
    <description>Event free survival (EFS) defined as time (days) between the date of enrolment and the earliest occurence of anyone of the following: progression based on RECIST 1.1 criteria; tumor recurrence; death to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 months</time_frame>
    <description>Overall survival (OS) defined as time between the date of the enrolment and the death to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 months</time_frame>
    <description>Progression free survival (PFS) defined as time between the date of the enrolment and the date tumor progression based on RECIST 1.1criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of treatment response</measure>
    <time_frame>2 months</time_frame>
    <description>Rate of treatment response (CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease) based on RECIST 1.1 criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Glioblastoma (GBM)</condition>
  <condition>DIPG</condition>
  <condition>Brainstem Glioma, Pediatric</condition>
  <condition>Diffuse Spinal Glioma</condition>
  <condition>Bilateral Thalamic Glioma</condition>
  <condition>Gliomatosis Cerebri</condition>
  <condition>Anaplastic Astrocytoma</condition>
  <condition>Midline Diffuse Glioma</condition>
  <arm_group>
    <arm_group_label>Doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated with Weller-Stupp protocol: initial radiotherapy (1.8 Gy/die, days 1-5; total dose 54-60 Gy) with concomitant oral temozolomide (75mg/m2/die, days 1-7) per 6 weeks.
At week 10 (4 weeks after the chemo-radiotherapy treatment completion): 1 cycle of oral temozolomide (150-180 mg/m2, days 1-5)
At week 14 (8 weeks after the chemo-radiotherapy treatment completion) 1 cycle of prolonged infusion of Doxorubicin (25mg/m2/die in 24 hours, days 1-4; total cumulative dose 100 mg/m2).
At week 18 (4 weeks after the end of doxorubicin administration): 16 cycles of oral temozolomide (initial dose of 150 mg/m2 increasing to 180 mg/m2 days 1-5, 28-day cycle).
Oral valproic acid (20-30 mg/Kg/die bid) is administered from week 1 until the last treatment day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <arm_group_label>Doxorubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females patients, aged &gt;3 years and &lt; 30 years;

          -  Newly diagnosed of GBM, DIPG, diffuse brainstem glioma, diffuse spinal glioma,
             bilateral thalamic glioma, gliomatosis cerebri, anaplastic astrocytoma;

          -  Patients undergone either surgery or biopsy only;

          -  No prior chemotherapy and/or radiotherapy;

          -  Life expectancy ≥ 4 weeks;

          -  Karnofsky/Lansky ≥ 40 %;

          -  Written informed consent obtained from the patient/parents or legal representative;

          -  Adequate hematological function (leucocyte ≥ 2.0 x 10^9/l -Hemoglobin ≥ 10 g/dl -
             platelet ≥ 50 x 10^9 /l);

          -  Adequate liver function (total bilirubin ≤ 2.5 x ULN - ALT/AST ≤ 5.0 x ULN);

          -  Adequate renal function (serum creatinine ≤ 1.5 x ULN);

          -  Adherence to trial treatment and compliance with the protocol

        Exclusion Criteria:

          -  Any disease or condition that contraindicates the use of the study drug (es. serious
             mental retardation, brain palsy, congenital syndrome, cardiomyopathy)

          -  Prior anti-cancer therapy

          -  Pregnancy or breastfeeding

          -  Non adequate contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Iacopo Sardi, MD, PhD</last_name>
    <phone>+390555662631</phone>
    <email>iacopo.sardi@meyer.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Meyer Children's Hospital</name>
      <address>
        <city>Florence</city>
        <zip>50145</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iacopo Sardi, MD, PhD</last_name>
      <phone>+390555662631</phone>
      <email>iacopo.sardi@meyer.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C, De Maria R. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ. 2006 Jul;13(7):1238-41. Epub 2006 Feb 3.</citation>
    <PMID>16456578</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96.</citation>
    <PMID>15758009</PMID>
  </reference>
  <reference>
    <citation>Ananda S, Nowak AK, Cher L, Dowling A, Brown C, Simes J, Rosenthal MA; Cooperative Trials Group for Neuro-Oncology (COGNO). Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. J Clin Neurosci. 2011 Nov;18(11):1444-8. doi: 10.1016/j.jocn.2011.02.026. Epub 2011 Aug 2.</citation>
    <PMID>21813279</PMID>
  </reference>
  <reference>
    <citation>Beier CP, Schmid C, Gorlia T, Kleinletzenberger C, Beier D, Grauer O, Steinbrecher A, Hirschmann B, Brawanski A, Dietmaier C, Jauch-Worley T, Kölbl O, Pietsch T, Proescholdt M, Rümmele P, Muigg A, Stockhammer G, Hegi M, Bogdahn U, Hau P. RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study. BMC Cancer. 2009 Sep 2;9:308. doi: 10.1186/1471-2407-9-308.</citation>
    <PMID>19725960</PMID>
  </reference>
  <reference>
    <citation>Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E, Pollack IF. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol. 2011 Apr;13(4):410-6. doi: 10.1093/neuonc/noq205. Epub 2011 Feb 22.</citation>
    <PMID>21345842</PMID>
  </reference>
  <reference>
    <citation>Krauze AV, Myrehaug SD, Chang MG, Holdford DJ, Smith S, Shih J, Tofilon PJ, Fine HA, Camphausen K. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):986-992. doi: 10.1016/j.ijrobp.2015.04.038. Epub 2015 Apr 30.</citation>
    <PMID>26194676</PMID>
  </reference>
  <reference>
    <citation>Lesniak MS, Upadhyay U, Goodwin R, Tyler B, Brem H. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res. 2005 Nov-Dec;25(6B):3825-31. Erratum in: Anticancer Res. 2006 Jan-Feb;26(1a):445.</citation>
    <PMID>16312042</PMID>
  </reference>
  <reference>
    <citation>Masoudi A, Elopre M, Amini E, Nagel ME, Ater JL, Gopalakrishnan V, Wolff JE. Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res. 2008 Jul-Aug;28(4C):2437-42.</citation>
    <PMID>18751431</PMID>
  </reference>
  <reference>
    <citation>Stan AC, Casares S, Radu D, Walter GF, Brumeanu TD. Doxorubicin-induced cell death in highly invasive human gliomas. Anticancer Res. 1999 Mar-Apr;19(2A):941-50.</citation>
    <PMID>10368637</PMID>
  </reference>
  <reference>
    <citation>van Dalen EC, van der Pal HJ, Caron HN, Kremer LC. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD005008. doi: 10.1002/14651858.CD005008.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;3:CD005008.</citation>
    <PMID>19821337</PMID>
  </reference>
  <reference>
    <citation>Veringa SJ, Biesmans D, van Vuurden DG, Jansen MH, Wedekind LE, Horsman I, Wesseling P, Vandertop WP, Noske DP, Kaspers GJ, Hulleman E. In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma. PLoS One. 2013 Apr 29;8(4):e61512. doi: 10.1371/journal.pone.0061512. Print 2013.</citation>
    <PMID>23637844</PMID>
  </reference>
  <reference>
    <citation>Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011 Sep 20;77(12):1156-64. doi: 10.1212/WNL.0b013e31822f02e1. Epub 2011 Aug 31.</citation>
    <PMID>21880994</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Meyer Children's Hospital</investigator_affiliation>
    <investigator_full_name>Iacopo Sardi</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>glioblastoma multiforme</keyword>
  <keyword>high grade glioma</keyword>
  <keyword>diffuse intrinsic pontine glioma</keyword>
  <keyword>DIPG</keyword>
  <keyword>doxorubicin</keyword>
  <keyword>temozolomide</keyword>
  <keyword>malignant glioma</keyword>
  <keyword>Brainstem Glioma</keyword>
  <keyword>diffuse spinal glioma</keyword>
  <keyword>bilateral thalamic glioma</keyword>
  <keyword>Anaplastic Astrocytoma</keyword>
  <keyword>Gliomatosis Cerebri</keyword>
  <keyword>Midline Diffuse Glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Neoplasms, Neuroepithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

